MAP1LC3A and B-cell chronic lymphocytic leukemia: This is also supported by the absence of altered levels of autophagic markers, LC3A/B-I and LC3A/B-II, following SRF231 treatment in primary CLL cells or Ri-1 lymphoma cells (Suppl.